文献速递心律失常

房颤合并慢性肝病患者中直接口服抗凝药与华法林的比较有效性与安全性:全国队列研究

Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
PubMed 文献 · Circulation · 2023-02-10

主要结局为缺血性卒中/系统性栓塞住院和大出血住院。结果显示DOAC整体及阿哌沙班较华法林显著降低缺血性卒中/系统性栓塞住院风险,DOAC整体、阿哌沙班和利伐沙班较华法林降低大出血住院风险,但利伐沙班较阿哌沙班大出血风险更高。

要点

  • DOAC整体较华法林降低缺血性卒中/系统性栓塞住院风险(HR 0.64)。
  • 阿哌沙班较华法林降低缺血性卒中/系统性栓塞住院风险(HR 0.40)。
  • 利伐沙班较阿哌沙班增加大出血住院风险(HR 1.59)。

核心结论

  • 在房颤合并慢性肝病患者中,DOAC整体较华法林降低缺血性卒中/系统性栓塞住院和大出血住院风险,但不同DOAC之间及与华法林比较的临床结局存在差异。

主要发现

  • 缺血性卒中/系统性栓塞住院发生率(每100人年):DOAC整体2.2、阿哌沙班1.4、利伐沙班2.6、华法林4.4。
  • 大出血住院发生率(每100人年):DOAC整体7.9、阿哌沙班6.5、利伐沙班9.1、华法林15.0。
  • 经逆概率治疗加权后,DOAC整体(HR 0.64,95%CI 0.46-0.90)和阿哌沙班(HR 0.40,95%CI 0.19-0.82)较华法林显著降低缺血性卒中/系统性栓塞住院风险;利伐沙班 vs 华法林(HR 0.76,95%CI 0.47-1.21)及利伐沙班 vs 阿哌沙班(HR 1.73,95%CI 0.91-3.29)无显著差异。
  • 大出血住院风险:DOAC整体较华法林降低(HR 0.69,95%CI 0.58-0.82),阿哌沙班较华法林降低(HR 0.60,95%CI 0.46-0.78),利伐沙班较华法林降低(HR 0.79,95%CI 0.62-1.0);利伐沙班较阿哌沙班升高(HR 1.59,95%CI 1.18-2.14)。

临床怎么用

  • 对于房颤合并慢性肝病患者,可考虑优先选用DOAC整体或阿哌沙班而非华法林以降低缺血性卒中/系统性栓塞及大出血住院风险。
  • 选择利伐沙班时需权衡其较阿哌沙班更高的的大出血住院风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefit-risk profile of direct oral anticoagulants (DOACs) compared with warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease is unclear. METHODS: We conducted a new-user, retrospective cohort study of patients with AF and chronic liver disease who were enrolled in a large, US-based administrative database between January 1, 2011, and December 31, 2017. We assessed the effectiveness and safety of DOACs (as a class and individually) compared with warfarin, and between DOACs in patients with AF and chronic liver disease. The primary outcomes were hospitalization for ischemic stroke/systemic embolism and hospitalization for major bleeding. Inverse probability treatment weights were used to balance the treatment groups on measured confounders. RESULTS: Overall, 10 209 participants were included, with 4421 (43.2%) on warfarin, 2721 (26.7%) apixaban, 2211 (21.7%) rivaroxaban, and 851 (8.3%) dabigatran. The incidence rates per 100 person-years for ischemic stroke/systemic embolism were 2.2, 1.4, 2.6, and 4.4 for DOACs as a class, apixaban, rivaroxaban, and warfarin, respectively. The incidence rates per 100 person-years for major bleeding were 7.9, 6.5, 9.1, and 15.0 for DOACs as a class, apixaban, rivaroxaban, and warfarin, respectively. After inverse probability treatment weights, the risk of hospitalization for ischemic stroke/systemic embolism was significantly lower between DOACs as a class (hazard ratio [HR], 0.64 [95% CI, 0.46-0.90]) or apixaban (HR, 0.40 [95% CI, 0.19-0.82]) compared with warfarin, but not significantly different between rivaroxaban versus warfarin (HR, 0.76 [95% CI, 0.47-1.21]) or rivaroxaban versus apixaban (HR, 1.73 [95% CI, 0.91-3.29]). Compared with warfarin, the risk of hospitalization for major bleeding was lower with DOACs as a class (HR, 0.69 [95% CI, 0.58-0.82]), apixaban (HR, 0.60 [95% CI, 0.46-0.78]), and rivaroxaban (HR, 0.79 [95% CI, 0.62-1.0]). However, the risk of hospitalization for major bleeding was higher for rivaroxaban versus apixaban (HR, 1.59 [95% CI, 1.18-2.14]). CONCLUSIONS: Among patients with AF and chronic liver disease, DOACs as a class were associated with lower risks of hospitalization for ischemic stroke/systemic embolism and major bleeding versus warfarin. However, the incidence of clinical outcomes among patients with AF and chronic liver disease varied between individual DOACs and warfarin, and in head-to-head DOAC comparisons.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Lawal, Aronow, Shobayo, et al. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study. Circulation. 2023. PMID: 36762560. doi:10.1161/CIRCULATIONAHA.122.060687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。